Beth Israel Deaconess Medical Center

Beth Israel

Beth Israel Deaconess Medical Center

As part of Johnson & Johnson’s response to the COVID-19 pandemic, one of our key collaborations within the Boston innovation community has been with Beth Israel Deaconess Medical Center (BIDMC). Building further on a long-standing collaboration in the development of Zika and HIV vaccines, Janssen and BIDMC were able to quickly jump start the collaborative development of Johnson & Johnson’s single-shot COVID-19 vaccine, which we’re providing on a not-for-profit basis for emergency pandemic use.*

The collaboration leveraged Dr. Dan Barouch’s scientific and medical expertise in the immunology and virology of serious infectious diseases and Janssen’s proven vaccine technologies, as well as expertise in development and manufacturing for global delivery.

*The Janssen COVID-19 Vaccine has not been approved/licensed by the FDA. bit.ly/2NKFjLs

IB banner